Pluri Inc. (PLUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pluri Inc. (PLUR) has a cash flow conversion efficiency ratio of 0.565x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.21 Million) by net assets ($-9.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pluri Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Pluri Inc. - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Pluri Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pluri Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluri Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BCWORLD PHARM. Co. Ltd
KQ:200780
|
0.020x |
|
Hyrican Informationssysteme Aktiengesellschaft
F:HYI
|
N/A |
|
Adler Group SA
F:ADJ
|
-0.079x |
|
Trend Gayrimenkul Yatirim Ortakligi AS
IS:TDGYO
|
0.222x |
|
Hitechpros
PA:ALHIT
|
0.017x |
|
Environmental Group Ltd (the)
AU:EGL
|
-0.067x |
|
Omnisystem Co.Ltd
KQ:057540
|
0.039x |
|
Lamor Corporation Oyj
HE:LAMOR
|
0.234x |
Annual Cash Flow Conversion Efficiency for Pluri Inc. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pluri Inc. from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Pluri Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-865.00K | $-18.21 Million | 21.053x | +732.61% |
| 2024-06-30 | $5.42 Million | $-18.02 Million | -3.328x | -122.77% |
| 2023-06-30 | $15.30 Million | $-22.86 Million | -1.494x | -31.73% |
| 2022-06-30 | $32.19 Million | $-36.50 Million | -1.134x | -109.68% |
| 2021-06-30 | $57.15 Million | $-30.91 Million | -0.541x | -15.07% |
| 2020-06-30 | $56.10 Million | $-26.37 Million | -0.470x | +65.18% |
| 2019-06-30 | $21.82 Million | $-29.45 Million | -1.350x | -79.97% |
| 2018-06-30 | $28.51 Million | $-21.38 Million | -0.750x | -4.98% |
| 2017-06-30 | $30.25 Million | $-21.61 Million | -0.714x | -47.17% |
| 2016-06-30 | $38.16 Million | $-18.52 Million | -0.485x | -36.98% |
| 2015-06-30 | $58.14 Million | $-20.61 Million | -0.354x | -15.14% |
| 2014-06-30 | $62.12 Million | $-19.12 Million | -0.308x | -4.74% |
| 2013-06-30 | $57.47 Million | $-16.89 Million | -0.294x | -238.65% |
| 2012-06-30 | $37.74 Million | $-3.27 Million | -0.087x | +34.53% |
| 2011-06-30 | $43.42 Million | $-5.75 Million | -0.133x | +90.24% |
| 2010-06-30 | $3.98 Million | $-5.41 Million | -1.358x | -8.18% |
| 2009-06-30 | $3.39 Million | $-4.26 Million | -1.256x | +35.54% |
| 2008-06-30 | $2.33 Million | $-4.54 Million | -1.948x | -274.03% |
| 2007-06-30 | $5.90 Million | $-3.07 Million | -0.521x | -116.39% |
| 2006-06-30 | $-644.23K | $-2.05 Million | 3.178x | +419.78% |
| 2005-06-30 | $1.80 Million | $-1.79 Million | -0.994x | +76.53% |
| 2004-06-30 | $357.01K | $-1.51 Million | -4.234x | -434.85% |
| 2003-06-30 | $490.42K | $-388.27K | -0.792x | -193.05% |
| 2002-06-30 | $-75.40K | $-64.16K | 0.851x | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more